Kineta News August 30, 2021Kineta Announces Participation at H.C. Wainwright 23rd Annual Global Investment Conference >> August 30, 2021Kineta Announces Participation at H.C. Wainwright 23rd Annual Global Investment ConferenceAugust 10, 2021Kineta Announces Patent Issuance of U.S. Patent for Composition of Matter of KCP506 >> August 10, 2021Kineta Announces Patent Issuance of U.S. Patent for Composition of Matter of KCP506July 27, 2021Kineta Announces Successful Completion of Pre-IND Meeting with the FDA for KVA12.1 >> July 27, 2021Kineta Announces Successful Completion of Pre-IND Meeting with the FDA for KVA12.1July 20, 2021Kineta and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-VISTA Antibody >> July 20, 2021Kineta and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-VISTA AntibodyJuly 14, 2021Kineta Announces First Participant Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of KCP506 >> July 14, 2021Kineta Announces First Participant Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of KCP506June 24, 2021Kineta’s Thierry Guillaudeux Participated on Multiple Panel Presentations During Virtual Symposium on VISTA >> June 24, 2021Kineta’s Thierry Guillaudeux Participated on Multiple Panel Presentations During Virtual Symposium on VISTAJune 7, 2021Kineta to Participate in “VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond” Virtual Symposium >> June 7, 2021Kineta to Participate in “VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond” Virtual SymposiumJune 1, 2021Kineta Closes $10 Million Financing Round to Advance Anti-VISTA Immuno-oncology Program >> June 1, 2021Kineta Closes $10 Million Financing Round to Advance Anti-VISTA Immuno-oncology ProgramApril 12, 2021Kineta Presents New Preclinical Data on its Lead VISTA Antagonist Antibody at the AACR Annual Meeting 2021 >> April 12, 2021Kineta Presents New Preclinical Data on its Lead VISTA Antagonist Antibody at the AACR Annual Meeting 2021March 25, 2021Kineta Presents Clinical Study Results of LHF-535 at the International Conference on Antiviral Research (ICAR) >> March 25, 2021Kineta Presents Clinical Study Results of LHF-535 at the International Conference on Antiviral Research (ICAR)March 3, 2021Kineta Presenting at Multiple Investor Conferences in March 2021 >> March 3, 2021Kineta Presenting at Multiple Investor Conferences in March 2021December 15, 2020Kineta Announces First Participant Dosed in Phase 1 Clinical Trial of KCP506, A Novel Non-Opioid for the Treatment of Chronic Pain >> December 15, 2020Kineta Announces First Participant Dosed in Phase 1 Clinical Trial of KCP506, A Novel Non-Opioid for the Treatment of Chronic PainDecember 9, 2020Kineta Presents New Preclinical Data at ESMO Virtual Congress 2020 on its VISTA Antagonist Antibodies >> December 9, 2020Kineta Presents New Preclinical Data at ESMO Virtual Congress 2020 on its VISTA Antagonist AntibodiesNovember 12, 2020Kineta Presents New Preclinical Data at the 2020 SITC Annual Meeting on its VISTA Antagonist Antibodies >> November 12, 2020Kineta Presents New Preclinical Data at the 2020 SITC Annual Meeting on its VISTA Antagonist AntibodiesOctober 20, 2020Kineta Presents New Preclinical Data on VISTA Antagonist Antibodies at AACR Special Conference on Tumor Immunology and Immunotherapy >> October 20, 2020Kineta Presents New Preclinical Data on VISTA Antagonist Antibodies at AACR Special Conference on Tumor Immunology and ImmunotherapyOctober 8, 2020Kineta to Extend Research Collaboration with Genentech to Develop a Novel Non-Opioid >> October 8, 2020Kineta to Extend Research Collaboration with Genentech to Develop a Novel Non-OpioidOctober 2, 2020Kineta to Participate in BIO Investor Forum Digital >> October 2, 2020Kineta to Participate in BIO Investor Forum DigitalSeptember 11, 2020Kineta to Present at September 2020 Virtual Investor Conferences >> September 11, 2020Kineta to Present at September 2020 Virtual Investor ConferencesAugust 12, 2020Kineta Receives Regulatory Approval for Initiation of Phase 1 Clinical Trials of KCP506 >> August 12, 2020Kineta Receives Regulatory Approval for Initiation of Phase 1 Clinical Trials of KCP506July 30, 2020Kineta Invited to Present at August 2020 Investor Conferences >> July 30, 2020Kineta Invited to Present at August 2020 Investor ConferencesJuly 3, 2020Kineta to Present at July 2020 Virtual Investor Events >> July 3, 2020Kineta to Present at July 2020 Virtual Investor EventsMay 5, 2020Kineta Closes Investment Round to Advance Early Preclinical Development of Immuno-oncology Programs >> May 5, 2020Kineta Closes Investment Round to Advance Early Preclinical Development of Immuno-oncology ProgramsApril 21, 2020Kineta Announces Formation of New Immuno-oncology Focused Scientific Advisory Board >> April 21, 2020Kineta Announces Formation of New Immuno-oncology Focused Scientific Advisory BoardMarch 25, 2020Kineta to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference >> March 25, 2020Kineta to Present at the Upcoming 2020 Solebury Trout Virtual Investor ConferenceFebruary 28, 2020Kineta Invited to Participate at the Opal Group’s Family Office Winter Forum in New York >> February 28, 2020Kineta Invited to Participate at the Opal Group’s Family Office Winter Forum in New YorkFebruary 27, 2020Kineta Invited to Participate at the Cowen and Company 40th Annual Health Care Conference >> February 27, 2020Kineta Invited to Participate at the Cowen and Company 40th Annual Health Care ConferenceFebruary 5, 2020Kineta Invited to Participate at the BIO CEO & Investor Conference >> February 5, 2020Kineta Invited to Participate at the BIO CEO & Investor ConferenceNovember 26, 2019Kineta Invited to Participate at the 2nd Annual Evercore ISI HealthCONx Conference >> November 26, 2019Kineta Invited to Participate at the 2nd Annual Evercore ISI HealthCONx ConferenceOctober 7, 2019Kineta Invited to Participate at October 2019 Investor Conferences >> October 7, 2019Kineta Invited to Participate at October 2019 Investor ConferencesAugust 29, 2019Kineta Invited to Participate at the H.C. Wainwright 21st Annual Global Investment Conference >> August 29, 2019Kineta Invited to Participate at the H.C. Wainwright 21st Annual Global Investment ConferenceAugust 12, 2019Kineta Invited to Participate at Solebury Trout’s 9th Annual CEO Roundtable Conference >> August 12, 2019Kineta Invited to Participate at Solebury Trout’s 9th Annual CEO Roundtable ConferenceAugust 6, 2019Kineta Secures $1.8 Million Funding Boost from Wellcome Trust on Positive Phase 1a Clinical Study Results with LHF-535 >> August 6, 2019Kineta Secures $1.8 Million Funding Boost from Wellcome Trust on Positive Phase 1a Clinical Study Results with LHF-535July 15, 2019Kineta Secures NIAID Grant Worth Up to $5.8M to Evaluate LHF-535 in Arenaviruses >> July 15, 2019Kineta Secures NIAID Grant Worth Up to $5.8M to Evaluate LHF-535 in ArenavirusesMay 28, 2019Kineta Invited to Participate at the Oppenheimer Summit for Emerging Life Sciences Conference >> May 28, 2019Kineta Invited to Participate at the Oppenheimer Summit for Emerging Life Sciences ConferenceMarch 29, 2019Kineta Invited to Present at the 2019 Life Science Innovation Northwest Conference >> March 29, 2019Kineta Invited to Present at the 2019 Life Science Innovation Northwest ConferenceDecember 17, 2018Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies >> December 17, 2018Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer ImmunotherapiesSeptember 5, 2018Kineta Initiates First-in-Human Clinical Trial of LHF-535 a Novel Therapy for Lassa Fever >> September 5, 2018Kineta Initiates First-in-Human Clinical Trial of LHF-535 a Novel Therapy for Lassa FeverApril 16, 2018Kineta to Collaborate on the Development of a Novel Non-Opioid Pain Therapy with Genentech >> April 16, 2018Kineta to Collaborate on the Development of a Novel Non-Opioid Pain Therapy with GenentechApril 5, 2018Kineta Immuno-oncology Unveils New Data Demonstrating Tumor Immunity in Multiple Tumor Models >> April 5, 2018Kineta Immuno-oncology Unveils New Data Demonstrating Tumor Immunity in Multiple Tumor ModelsMarch 23, 2018Kineta Immuno-oncology to Present at Keystone Symposia on Molecular and Cellular Biology: Cancer Immunotherapy Combinations Conference >> March 23, 2018Kineta Immuno-oncology to Present at Keystone Symposia on Molecular and Cellular Biology: Cancer Immunotherapy Combinations ConferenceJanuary 22, 2018Kineta Immuno-oncology Announces Presentation on Novel RIG-I Agonists at Immuno-Oncology Frontiers World Conference >> January 22, 2018Kineta Immuno-oncology Announces Presentation on Novel RIG-I Agonists at Immuno-Oncology Frontiers World ConferenceJanuary 2, 2018Kineta Appoints Michael Banks as New Chief Financial Officer >> January 2, 2018Kineta Appoints Michael Banks as New Chief Financial OfficerJune 12, 2017Kineta to Present at Symposium on Pandemic Preparedness >> June 12, 2017Kineta to Present at Symposium on Pandemic PreparednessMay 15, 2017Inside Perspectives on Cancer Immunotherapy: An Interview with Kineta’s Shawn Iadonato, WuXi AppTec >> May 15, 2017Inside Perspectives on Cancer Immunotherapy: An Interview with Kineta’s Shawn Iadonato, WuXi AppTecMay 4, 2017RLR Agonists Seen to Promote Immune Response Against Colon Cancer Cells in Early Study, Colon Cancer News Today >> May 4, 2017RLR Agonists Seen to Promote Immune Response Against Colon Cancer Cells in Early Study, Colon Cancer News TodayApril 25, 2017Kineta to Present at Symposium on Next-Generation Therapeutics for the Treatment of Pain >> April 25, 2017Kineta to Present at Symposium on Next-Generation Therapeutics for the Treatment of PainApril 21, 2017Kineta to Present at the Planet MicroCap Showcase 2017 >> April 21, 2017Kineta to Present at the Planet MicroCap Showcase 2017April 4, 2017Kineta to Present at the 24th Annual Future Leaders in the Biotech Industry Conference >> April 4, 2017Kineta to Present at the 24th Annual Future Leaders in the Biotech Industry ConferenceMarch 23, 2017Kineta RLR Agonist Demonstrates Tumor Regression and an Adaptive Immune Response in Colon Carcinoma Model >> March 23, 2017Kineta RLR Agonist Demonstrates Tumor Regression and an Adaptive Immune Response in Colon Carcinoma ModelFebruary 22, 2017KCP-400 Relieves Chronic Pain and Demonstrates Disease Modifying Effects >> February 22, 2017KCP-400 Relieves Chronic Pain and Demonstrates Disease Modifying EffectsJanuary 6, 2017Kineta to Present at Biotech Showcase Investor Conference during JP Morgan Week in San Francisco >> January 6, 2017Kineta to Present at Biotech Showcase Investor Conference during JP Morgan Week in San FranciscoOctober 31, 2016Kineta CEO to Speak on Immuno-oncology Panel at the BIO Investor Forum >> October 31, 2016Kineta CEO to Speak on Immuno-oncology Panel at the BIO Investor ForumOctober 19, 2016Kineta CEO Unveils its Immuno-oncology Program at the BIO Investor Forum >> October 19, 2016Kineta CEO Unveils its Immuno-oncology Program at the BIO Investor ForumAugust 18, 2016UPDATE: Kineta Secures Funding to Expand Testing of Broad Spectrum Antivirals Against Zika Virus UPDATE >> August 18, 2016UPDATE: Kineta Secures Funding to Expand Testing of Broad Spectrum Antivirals Against Zika Virus UPDATEJuly 31, 2016Kineta Secures NIAID Funding to Expand Testing of Immune Modulators >> July 31, 2016Kineta Secures NIAID Funding to Expand Testing of Immune ModulatorsMay 16, 2016Kineta Presents Promising New Vaccine Adjuvant Data at American Association of Immunologists Annual Meeting >> May 16, 2016Kineta Presents Promising New Vaccine Adjuvant Data at American Association of Immunologists Annual MeetingMay 11, 2016Kineta wins $7.2M award to develop antiviral drug focused on Lassa fever, GeekWire >> May 11, 2016Kineta wins $7.2M award to develop antiviral drug focused on Lassa fever, GeekWireMay 5, 2016Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical Trials >> May 5, 2016Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical TrialsMay 5, 2016Seattle biotech Kineta wins $7.2M award for drug development, Puget Sound Business Journal >> May 5, 2016Seattle biotech Kineta wins $7.2M award for drug development, Puget Sound Business JournalApril 22, 2016Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune Antivirals >> April 22, 2016Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune AntiviralsMarch 31, 2016Kineta Announces Promising New Data for KIN 1148 – a Novel Vaccine Adjuvant for Highly Pathogenic Flu >> March 31, 2016Kineta Announces Promising New Data for KIN 1148 – a Novel Vaccine Adjuvant for Highly Pathogenic FluMarch 22, 2016Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress >> March 22, 2016Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congressload more
